4.6 Article

Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer

Journal

PLOS ONE
Volume 10, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0133896

Keywords

-

Funding

  1. National Natural Science Foundation of China [30971143, 30972936, 81302303]
  2. Shanghai United Developing Technology Project of Municipal Hospitals [SHDC12010116]
  3. Key Clinical Program of the Ministry of Health
  4. Shanghai Key laboratory of Breast Cancer [12DZ2260100]

Ask authors/readers for more resources

Purpose The purpose of this study was to determine the prognostic role of ten eleven translocation (TET) family proteins and DNA glycosylase (TDG) in patients with early breast cancer (EBC). Methods Expression of mRNAs encoding TET1-3 and TDG in 162 breast cancer tissues was quantified using real-time polymerase chain reaction analysis. The general characteristics of patients and clinicopathologic factors were collected. Estimation of patient survival was calculated using the Kaplan-Meier method, and independent prognostic indicators were analyzed using Cox regression analysis. Results The level of TET1 mRNA was significantly related to overall survival (OS) (P = 0.022). Multivariate analysis shows that the TNM stage was an independent predictor of disease-free survival (DFS) (HR = 1.761, 95% CI: 1.124-2.761, P = 0.014) and OS (HR = 2.135, 95% CI: 1.070-4.263, P = 0.032). Further, in patients with EBC who were treated with anthracy-clines, Kaplan-Meier analysis indicates that the levels of TET3 and TDG mRNAs were related to DFS (P = 0.026 and 0.030, respectively), and multivariate analysis reveals that high levels of TET3 (HR = 1.944, 95% CI: 1.029-3.672, P = 0.040) and TDG (HR = 2.178, 95% CI: 1.140-4.163, P = 0.018) mRNAs were independent indicators of favorable DFS. Conclusions Our study indicates that EBC patients with decreased expression of TET1 mRNA had worse OS and that the levels of TET3 and TDG mRNAs were independent prognostic factors for patients who received anthracycline chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available